WCN24-1063 The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in Diabetic Nephropathy and Non Diabetic Renal Disease in Diabetes Mellitus type2 Patients
Saved in:
| Main Authors: | Maru Navarro, Montserrat Gomà, Ariel Tango, Oana Rap, Cristina Cabrera, Ana Sánchez, Neus Farré, Pilar Ruiz, Meritxell Ibernon |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924005473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01) -
Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01) -
Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study)
by: Ayako Shigeta, et al.
Published: (2025-05-01) -
Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01) -
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.
by: Yongin Cho, et al.
Published: (2025-01-01)